Session » Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1087

Association between Cigarette Smoking and Systemic Lupus Erythematosus – a Bayesian Multivariate Meta-Analysis of Case-Control and Cohort Studies

9:00AM-11:00AM: Abstract Number: 1081

Associations between Daily Alcohol Intake and SLE-Related Cytokines and Chemokines U.S. Female Nurses without SLE

9:00AM-11:00AM: Abstract Number: 1090

Cell-Free Mitochondrial DNA As a Novel Biomarker in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1083

Changes of Innate Lymphoid Cells in Peripheral Blood of Patients with Systemic Lupus Erythematosus and Its Correlations with Clinical Markers

9:00AM-11:00AM: Abstract Number: 1089

Commensal Gut Bacteria of Anti-Ro Positive Mothers of Children with Neonatal Lupus in Aggregate Resemble Healthy Subjects without Overt Dysbiosis of Abundance of Microorganisms

9:00AM-11:00AM: Abstract Number: 1098

Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)

9:00AM-11:00AM: Abstract Number: 1084

Dysfunction of the DNASE1L3 Pathway and Antigen Accumulation in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1094

Endogenous Ifnβ Production Is Required for Efficient BCR Crosslinking and Survival of SLE B Cells

9:00AM-11:00AM: Abstract Number: 1101

Extracellular Vesicle-Mediated Delivery of EBV SMALL RNA (EBER1) Activates LUPUS Nephritis Related Antiviral Immunity in Tubular Epithelial CELLS VIA TLR3

9:00AM-11:00AM: Abstract Number: 1080

Hypomethylation of STAT1 and HLA-DRB1 in CD8+ T Cells Is Associated with Type-I Interferon-Dependent HLA-DRB1 Overexpression and Activation of Autologous CD4+ T Cells in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1095

IFN Gene Expression Correlates with Frequency of Circulating Switched Memory B-Cells in Patients with Incomplete Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1092

Immune Complex-Driven Neutrophil Activation and BAFF Production Promote B Cell Activation and Autoantibody Production in Human SLE

9:00AM-11:00AM: Abstract Number: 1086

Low-Dose IL-2 Combined with Rapamycin Efficiently Promotes Remission of Refractory Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1085

Natural Gingerols Inhibit Neutrophil Extracellular Trap Release Elicited By Lupus Autoantibodies

9:00AM-11:00AM: Abstract Number: 1099

Ongoing DNA Damage, Chromatin Deregulation and Defective DNA Damage Response in Systemic Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1082

Peripheral Blood CD11c+ CD21- Age-Associated B Cells (ABCs) in Human Systemic Lupus Erythematosus Are Associated with Innate Type III Interferon and Disease Activity

9:00AM-11:00AM: Abstract Number: 1079

Plasma Metabolomic Analysis Combined with Transcriptome Data Has Revealed the Importance of Amino Acids Homeostasis in SLE Pathogenesis

9:00AM-11:00AM: Abstract Number: 1088

Pro-Inflammatory and Regulatory Soluble Mediator Pathways Vary between African American and European American SLE Patients

9:00AM-11:00AM: Abstract Number: 1091

Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is Essential for T Lymphocyte Homeostasis and Decreased Levels of SRSF1 Correlate with Lymphopenia in SLE Patients

9:00AM-11:00AM: Abstract Number: 1093

Serologic Evidence Linking Epstein Barr Virus Reactivation, Heightened Interferon Pathway Activation and Increased Disease Activity in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1097

Spatial-Time Cluster Analysis of SLE Disease Activity

9:00AM-11:00AM: Abstract Number: 1100

The Frequencies and Molecular Profiles of CD16+ Monocyte Subsets in Patients with Systemic Lupus Erythematosus, Primary Antiphospholipid Syndrome, and Antiphospholipid Syndrome with Lupus, Identify Specific Clinical Features of These Diseases

9:00AM-11:00AM: Abstract Number: 1096

Unexpected Association between Health-Related Quality of Life and the Blood Interferon Modular Transcriptional Signatures in Patients with Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].